Gastrointestinal Stromal Tumor (GIST) Clinical Trial
Official title:
An Open-Label, Randomised, Multi-Centre, Phase II Study to Investigate the Safety and Efficacy of AT13387, Either as Monotherapy or in Combination With Imatinib, in Patients With Unresectable and/or Metastatic Malignant GIST Whose Tumour Has Progressed Following Treatment With a Maximum of Three Tyrosine Kinase Inhibitors
NCT number | NCT01294202 |
Other study ID # | AT13387/0002 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | March 2011 |
Est. completion date | July 2014 |
Verified date | January 2020 |
Source | Astex Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to investigate if an investigational drug called AT13387 is
active against Gastrointestinal Stromal Tumor (GIST) that is resistant to other treatments,
and to understand more about the safety of AT13387.
Most subjects in the study will receive AT13387 along with another drug called imatinib
(Gleevec). Imatinib is a standard (approved) drug for treating patients with GIST. Some
patients may receive AT13387 on its own. As a result, we shall begin to understand the
effects of AT13387 given on its own and when combined with imatinib.We shall also find out
more about the side-effects of AT13387, and more about how the body breaks down (metabolizes)
AT13387.
Status | Completed |
Enrollment | 26 |
Est. completion date | July 2014 |
Est. primary completion date | April 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Ability to understand the risks of the study and to provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations). - Age 18 years or older. - Unresectable and/or metastatic malignant GIST with objective progression of disease following treatment with a maximum of 3 tyrosine kinase inhibitors (TKIs) including imatinib. To clarify, it is the number of TKIs - up to a maximum of three agents, including imatinib - that is the criterion for entry, not the number of prior courses of TKI treatment. - Measurable disease. - ECOG performance status 0 or 1. - Negative blood or urine pregnancy test (within 7 days prior to commencing treatment), or documented evidence of surgical sterility, or natural or treatment-induced post-menopausal status with last menses >1 year ago. - Willing to provide a tissue block or unstained slides of archived tumour for central pathology review and genotyping, or a full pathology report and results of genotyping of a previous tumour sample, or willing to undergo a new tumour biopsy for central pathology review and genotyping during the screening period of the study (prior to dosing) Exclusion Criteria: - Pregnancy or lactation (women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to commencing treatment ). Male and female patients of childbearing potential must use appropriate birth control (abstinence, barrier methods, oral contraceptives and/or intrauterine devices) during the entire duration of the study, or the patient must be surgically sterile (with documentation in the patient's medical records). - Impaired liver function, as evidenced by prior liver segmentectomy or hemi-hepatectomy; or alanine or aspartate aminotransferase (ALAT/ASAT) >2.5x ULN; or alkaline phosphatase >2.0x ULN; or bilirubin >2.0x ULN. - Abnormal clotting, as evidenced by PT or PTT >1.5x ULN, or therapeutic/prophylactic anticoagulation. - Renal impairment, defined as either serum creatinine higher than the institution ULN,or estimated creatinine clearance lower than LLN (i.e. patients should have both normal serum creatinine, and normal estimated creatinine clearance) - Impaired marrow function, defined as haemoglobin <9.0 g/dL, neutrophils <1.5 x10^9/L, or platelets <100 x10^9/L. Patients may receive a blood transfusion for anaemia to allow entry to the study but should not be transfusion-dependent. - Left ventricular ejection fraction <50% on echocardiography or MUGA scan. - Known metastases of the central nervous system. - Prior anticancer therapies including tyrosine kinase inhibitors (other than imatinib) not completed within 2 weeks or 5 half-lives of the agent (including known active metabolites) prior to treatment with study drug. Patients receiving imatinib should continue to receive imatinib (400 mg daily) throughout the screening period. - Clinically important intolerance or safety concerns with prior use of imatinib 400 mg daily. - Prior treatment with an HSP90 inhibitor. - Major surgery within 14 days prior to treatment with study drug, or failure to recover from the effects of such surgery. - Wide field radiotherapy within 4 weeks prior to treatment with study drug, limited field radiation within 2 weeks, or failure to recover from such therapies. - History of an ischaemic cardiac event or unstable cardiac disease within 3 months of study entry. - QTc >450 ms using Fredericia's correction. - Previous malignancy, except for basal cell and squamous cell skin carcinomas or carcinoma of the uterine cervix, unless treated with curative intent more than 2 years prior to study entry. - Evidence of severe or uncontrolled systemic medical conditions which make it undesirable for the patient to take part in the study, or which could jeopardize protocol compliance. Patients with multiple comorbidities and/or requiring multiple concomitant medications (especially conditions/medications which may impair renal function or predispose to renal impairment) should be discussed with the Astex Medical Monitor at the discretion of the Investigator before enrollment. - Prior history of infection with HIV, or known active hepatitis B or C viral infection (active screening for viral infections is not required for study entry). - Significant visual impairment such that in the opinion of the investigator, further minor deterioration would have unacceptable consequences (eg. loss of ability to drive or live at home. - The Safety Monitoring Committee may add other specific exclusion criteria to enhance the safety of the patients based on emerging safety data. |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University | Baltimore | Maryland |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Robert H. Lurie Cancer Center of Northwestern University | Chicago | Illinois |
United States | Duke University Medical Center | Durham | North Carolina |
United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Oregon Health and Sciences University | Portland | Oregon |
United States | Arizona Cancer Center at UMC North | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
Astex Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of reduction/stabilisation of tumour size at 4 months according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria | 4 months | ||
Secondary | Rate of reduction/stabilisation of tumour size at 6 months (6-month 'disease control rate' [DCR]), determined according to RECIST version 1.1 criteria. | 6 months | ||
Secondary | Progression-free survival at 6 months, and estimated proportion of patients surviving at 6 months. | 6 months | ||
Secondary | Objective responses, using RECIST version 1.1 criteria | 6 months | ||
Secondary | Changes in pharmacodynamic biomarkers assessed in tumour biopsies and plasma samples, and changes in tumour metabolism by Fludeoxyglucose - Positron emission tomography scans (FDG-PET). | 6 months | ||
Secondary | Relationships between KIT and PDGRFA tumour mutational status, changes in tumour dimensions, and exploratory pharmacodynamic biomarkers. | 6 months | ||
Secondary | Pharmacokinetic profile of AT13387 given in combination with imatinib. | 6 months | ||
Secondary | Treatment emergent adverse events, classified by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02574663 -
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT01991379 -
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
|
Phase 1/Phase 2 | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Completed |
NCT00623831 -
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
|
Phase 1 | |
Completed |
NCT00464620 -
Trial of Dasatinib in Advanced Sarcomas
|
Phase 2 | |
Completed |
NCT00785785 -
A Study of Nilotinib Versus Imatinib in GIST Patients
|
Phase 3 | |
Recruiting |
NCT02443948 -
Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)
|
N/A | |
Recruiting |
NCT01034670 -
Advanced Gastrointestinal Endoscopic Imaging
|
N/A | |
Completed |
NCT00867113 -
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
Active, not recruiting |
NCT01391611 -
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
|
Phase 2 | |
Terminated |
NCT02452424 -
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03594422 -
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05453292 -
Endoscopic Ultrasound Radiofrequency Ablation for GISTs
|
N/A | |
Completed |
NCT00780494 -
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
|
Phase 2 | |
Recruiting |
NCT04557969 -
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
|
||
Completed |
NCT03404076 -
Unifying Advanced Treatment With Advanced Imaging
|
||
Recruiting |
NCT04821895 -
Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients
|
||
Completed |
NCT01316263 -
A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
|
Phase 2 | |
Terminated |
NCT00767234 -
Permission to Collect Blood Over Time for Research
|
N/A | |
Recruiting |
NCT01048281 -
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
|